�Takeda Pharmaceutical Company Limited (TOKYO:4502) and Affymax, Inc. (Nasdaq:AFFY) today announced their agreement to suspend co-development of Hematide� to treat chemotherapy-induced anaemia and to focus all development efforts for Hematide� on the treatment of chronic kidney disease related anemia. Takeda and Affymax continue to be bucked up by the potential of bringing Hematide, a convenient, once monthly treatment option, to the millions of chronic kidney disease patients suffering from anemia and believe this represents a significant opportunity for the two companies.
Takeda has been conducting Phase I clinical studies of Hematide� for the treatment of chemotherapy-induced genus Anemia in the U.S. and Japan. However, the companies have decided to set aside development of Hematide in oncology and not to enroll new patients in the ongoing Phase I clinical trial of the product in chemotherapy-induced anaemia given the uncertain regulatory landscapes for
Wednesday 10 September 2008
Subscribe to:
Posts (Atom)